Detalhe da pesquisa
1.
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Blood
; 121(14): 2739-42, 2013 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23380743
2.
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Blood
; 119(8): 1838-43, 2012 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22174159
3.
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Blood
; 117(14): 3733-6, 2011 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-21346253
4.
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Blood
; 116(25): 5497-500, 2010 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20833982
5.
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.
Blood
; 116(12): 2033-9, 2010 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-20562327
6.
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Nat Commun
; 13(1): 6922, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376307
7.
Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Nat Commun
; 12(1): 5450, 2021 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521827
8.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Blood
; 112(12): 4437-44, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18716134
9.
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica
; 95(2): 224-31, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19833633
10.
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
Br J Haematol
; 145(3): 373-5, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19344397
11.
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.
Blood
; 116(6): 1014-6, 2010 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-20705771
12.
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Lancet
; 362(9384): 617-9, 2003 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-12944062
13.
Cancer-selective targeting of the NF-κB survival pathway with GADD45ß/MKK7 inhibitors.
Cancer Cell
; 26(4): 495-508, 2014 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25314077
14.
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
Br J Haematol
; 141(5): 745-7, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18331365
15.
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
J Clin Oncol
; 30(3): 232-8, 2012 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22067393
16.
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
J Clin Oncol
; 28(14): 2381-8, 2010 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20385986
17.
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45ß/MKK7 Inhibitors.
Cancer Cell
; 26(6): 938, 2014 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28898681
18.
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
J Clin Oncol
; 26(29): 4806-13, 2008 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18645191
19.
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
J Clin Oncol
; 26(20): 3358-63, 2008 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519952
20.
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Cancer
; 103(9): 1850-5, 2005 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15786422